Our goal was to characterize the BNP forms present in explanted human heart tissue and matching plasma in patients with end-stage heart failure and also characterize the newly secreted forms of BNP in coronary sinus plasma in patients with preserved left ventricular systolic function undergoing cardiac catheterization.
July 27, 2015 /PRNewswire-iReach/ -- A new clinical trial to test how a high dose of stem cells delivered via a method called "retrograde coronary sinus infusion" affects end stage heart failure patients is showing promising results.
saturation of venous blood at two positions of a probe with curved geometry to achieve that in the Vena Cava (where all the returning blood of the body except of the heart flows) and in the Coronary Sinus (where the returned blood of the heart flows).
Transthoracic and transesophageal ECGs demonstrated a dilated right ventricle and atrium, right ventricular concentric hypertrophy, and a persisting left superior vena cava, which drained into the dilated coronary sinus (Fig 1).
The trial is intended to evaluate the safety and clinical effect of Harvest's BMAC autologous cell composition to treat patients with Congestive Heart Failure (CHF) when using a minimally invasive retrograde coronary sinus delivery.